REVIEW ARTICLE



Presentation and clinical course of pediatric-onset versus adult-onset Takayasu arteritis—a systematic review and meta-analysis

Durga Prasanna Misra¹ · Upendra Rathore¹ · Chirag Rajkumar Kopp² · Pallavi Patro³ · Vikas Agarwal¹ · Aman Sharma²

Received: 30 June 2022 / Revised: 24 July 2022 / Accepted: 26 July 2022 / Published online: 5 August 2022 © The Author(s), under exclusive licence to International League of Associations for Rheumatology (ILAR) 2022

Abstract

Takayasu arteritis (TAK) is a less common large-vessel vasculitis which can occur in either children or adults. However, differences between pediatric-onset and adult-onset TAK have not been systematically analyzed. We undertook a systematic review (pre-registered on PROSPERO, identifier CRD42022300238) to analyze differences in clinical presentation, angiographic involvement, treatments, and outcomes between pediatric-onset and adult-onset TAK. We searched PubMed (MEDLINE and PubMed Central), Scopus, major recent international rheumatology conference abstracts, Cochrane database, and clinicaltrials.gov, and identified seven studies of moderate to high quality comparing pediatric-onset and adult-onset TAK. Meta-analysis of 263 pediatric-onset and 981 adult-onset TAK suggested that constitutional features (fever, and in subgroup analyses, weight loss), hypertension, headache, and sinister features of cardiomyopathy, elevated serum creatinine, and abdominal pain were more frequent in pediatriconset TAK, whereas pulse loss/pulse deficit and claudication (particularly upper limb claudication) were more frequent in adult-onset TAK. Hata's type IV TAK was more common in pediatric-onset TAK, and Hata's type I TAK in adult-onset TAK. Children with TAK also appeared to require more intense immunosuppression with more frequent use of cyclophosphamide, biologic DMARDs, tumor necrosis factor alpha inhibitors, and, in subgroup analyses, tocilizumab in pediatric-onset TAK than in adult-onset TAK. Surgical or endovascular procedures, remission, and risk of mortality were similar in both children and adults with TAK. No studies had compared patient-reported outcome measures between pediatric-onset and adult-onset TAK. Distinct clinical features and angiographic extent prevail between pediatric-onset and adult-onset TAK. Clinical outcomes in these subgroups require further study in multicentric cohorts.

Key Points

- Adult-onset TAK more commonly presents with pulse loss/pulse deficit or claudication (particularly of the upper limbs).
- Angiographic type IV is more common in children, and type I in adults.

• Remission and mortality are similar in pediatric-onset and adult-onset TAK.

Keywords Aortitis syndrome \cdot Childhood onset \cdot Large-vessel vasculitis \cdot Pediatric onset \cdot Pediatric vasculitis \cdot Takayasu arteritis

☑ Durga Prasanna Misra durgapmisra@gmail.com; dpmisra@sgpgi.ac.in

Extended author information available on the last page of the article

Introduction

Takayasu arteritis (TAK) is a rare form of large-vessel vasculitis (LVV) that predominantly affects younger individuals [1]. Large-vessel inflammation associated with or without systemic features drive the pathogenesis of TAK [2–4]. While the onset of TAK is often insidious

[•] Pediatric-onset TAK more commonly presents with constitutional features, hypertension, cardiomyopathy, elevated serum creatinine, and abdominal pain.

and might progress to pulse loss without prominent symptoms, in rarer instances, the onset can be devastating with rapid-onset critical vascular occlusion resulting in stroke or myocardial infarction [1, 5]. The entities of pediatric-onset and adult-onset TAK are both well recognized. Separate classification criteria have been proposed for pediatric-onset TAK [6], distinct from the criteria commonly used for adult-onset TAK [7–9]. It is believed that pediatric-onset TAK has more prominent systemic symptoms and that the disease course might be more severe [10-12]. Until recently, few studies had compared pediatric-onset and adult-onset TAK [11]. Differences between the clinical presentation, angiographic involvement, treatment patterns, and outcomes between pediatric-onset and adult-onset TAK have not yet been systematically evaluated by pooling data across individual studies in the form of a systematic review with metaanalysis. Therefore, we undertook this systematic review to understand differences in the clinical presentation, angiographic extent, prevalent treatment practices, and outcomes between pediatric-onset and adult-onset TAK.

Methods

Protocol

The systematic review protocol was registered with the prospective international register of systematic reviews (PROSPERO identifier CRD42022300238). The systematic review was conducted in line with recommendations provided by the Cochrane collaboration [13]. The systematic review was reported to conform with Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA 2020, Supplementary Table S1) [14] and Meta-analysis of Observational Studies in Epidemiology (Supplementary Table S2) [15] reporting guidelines.

Literature searches

PubMed (both MEDLINE and PubMed Central) and Scopus, the Cochrane database of clinical trials (CEN-TRAL), the website of clinicaltrials.gov, conference abstracts of major international Rheumatology societies, viz., European Alliance of Associations for Rheumatology (EULAR, from 2018 to 2022), American College of Rheumatology (ACR, from 2018 to 2021), and Asia Pacific League of Associations for Rheumatology (from 2018 to 2021) were searched to identify articles related to pediatric-onset TAK. The search strategy is presented in Supplementary Table S3. Studies hitherto identified were screened to identify those comparing patients with pediatric-onset and adult-onset TAK. Literature searches were conducted on 10 January 2022 and updated on 23 May 2022. The updated search results are presented in the manuscript.

Inclusion criteria

Participants

Patients with pediatric-onset TAK either fulfilled the 2010 EULAR/Pediatric Rheumatology European Society (PRES)/Pediatric Rheumatology International Trials Organization (PRINTO) criteria for TAK [6], 2012 Chapel Hill Consensus Conference definition of TAK [5], or had a clinician diagnosis of TAK. Patients with adult-onset TAK either fulfilled the 1990 ACR classification criteria for TAK [7], the Ishikawa criteria [8], or Sharma's modification of Ishikawa criteria [9], 2012 Chapel Hill Consensus Conference definition of TAK [5], or had a clinician diagnosis of TAK.

Intervention and comparator groups

Patients with pediatric-onset TAK were compared with those with adult-onset TAK.

Outcomes

Clinical features at presentation, angiographic involvement (individual vessels involved as well as using any of the angiographic classification systems), treatments used at any time or at the last visit (corticosteroids, conventional disease-modifying antirheumatic drugs (DMARDs), biologic DMARDs, targeted synthetic DMARDs), surgical or endovascular procedures (with complications, if any), and outcomes (remission as defined by the clinician at any visit or at last follow-up, angiographic stabilization, damage scores, mortality) were all primary outcomes.

Types of studies

Since TAK is a rare disease and there are few clinical trials in TAK [16], both observational and interventional studies were considered for inclusion, provided they had included at least 5 patients with TAK.

Exclusion criteria

Original articles which presented information about pediatric-onset TAK without a comparator group of

adult-onset TAK were excluded. Review articles, case reports, letters to the editor not describing original data, or editorials were excluded.

Screening and data extraction

Titles and abstracts of studies derived from the search results were screened by two investigators independently (DPM, PP) and studies identified for full-text screening were further evaluated for eligibility, noting reasons for exclusion at each step. Results from PubMed and Scopus searches were exported using Endnote X9.3 and duplicates were removed. Searches conducted on conference abstracts, clinicaltrials.gov, and CENTRAL were done manually.

For the identified studies, data was extracted onto paper proformas by three investigators independently (DPM, UR, CRK). Any discrepancies were resolved by discussion with a fourth colleague (AS).

Quality assessment of individual studies

The quality of observational studies published as full text (but not conference abstracts) was assessed using the Newcastle–Ottawa scale. Selection of participants (out of 4), comparability of groups (out of 2), and outcome assessment (out of 3) were rated by two investigators (DPM and VA) independently. Discrepancies were resolved by discussion between investigators. Publication bias was ascertained only if there were at least ten studies available for a particular comparison [17].

Analysis of data

Detailed summary of findings tables were generated to detail demographic characteristics of participants in the identified studies, separately for pediatric-onset and adultonset TAK. Wherever means with standard deviations were not available in the papers, these were imputed from the median and quartiles 1 and 3 [18] or from the median with lower and upper limits of range [19] using formulae available in the published literature. Risk ratios for various categorical outcomes and effect size for continuous variables (using Hedges' g) for pediatric-onset vs adultonset TAK were pooled using inverse variance restricted maximum likelihood method with random effects using meta command on STATA 16.1 I/C. This technique automatically adjusted for zeros if any in the numerator of the risk ratios. Random effects model was chosen a priori due to the expected heterogeneity among studies resulting from inter-study differences such as those in inclusion criteria for patient selection, study design (prospective or retrospective), and different care settings. Pooled log risk ratios (with 95% confidence intervals) were calculated using this technique. Statistical heterogeneity of the pooled estimates was calculated using the I^2 statistic, with values > 50% indicative of significant heterogeneity. Wherever data could not be pooled across studies, standalone risk ratios with 95% confidence intervals were calculated using online calculators [20]. Subgroup analyses were pre-planned based on study design (prospective, retrospective, or both prospective and retrospective).

Results

Search results

Search results are detailed in Fig. 1 derived from the PRISMA flowchart. After screening and eligibility assessment as per criteria detailed previously, six full papers [21–26] and one conference abstract [27] were selected for qualitative and quantitative analysis.

Characteristics of included studies

Table 1 summarizes the characteristics of included studies. Overall, there were 263 patients with pediatric-onset TAK and 981 with adult-onset TAK. Six out of the seven identified studies were single-center studies, five were retrospective, whereas one each was prospective or both prospective and retrospective. Three studies defined pediatric-onset TAK as onset ≤ 18 years, three others as onset < 18 years, whereas another defined it as onset ≤ 16 years. Both pediatric-onset and adult-onset TAK had a predominance of female patients. Delay to diagnosis was similar in both groups. Delay to diagnosis could be pooled from three studies (Jales-Neto 2010, Aeschlimann 2019 and Karabacak 2021). Pooled delay to diagnosis was not significantly different between pediatric-onset and adult-onset TAK (effect size -0.36, 95% confidence interval -0.75to +0.03) without significant heterogeneity (Supplementary Fig. 1). Seven studies each had reported clinical presentation or angiographic extent of disease, whereas six studies each had reported treatments or outcomes comparatively between pediatric-onset and adult-onset TAK.

Quality assessment of individual studies

Two studies were of high quality (Newcastle–Ottawa scale score 7–9) and four others were of moderate quality (Newcastle–Ottawa scale score 4–6) [28]. Quality assessment could not be performed for the study published as a conference abstract alone (Cocchiara 2020)



Fig. 1 Search strategy derived from the PRISMA 2020 flowchart [14]

(Supplementary Table S4). Publication bias could not be evaluated due to a paucity of studies.

Comparisons between pediatric-onset and adult-onset TAK

Clinical features at presentation

Among vascular features, hypertension (with considerable statistical heterogeneity) was more frequent in pediatric-onset TAK, whereas pulse loss/pulse deficit and claudication were more frequent in adult-onset TAK. Cardiomyopathy was more frequent in pediatric-onset TAK. Among constitutional features, fever was more frequent in pediatric-onset TAK. Among neurological features, headache was more frequent in pediatric-onset TAK. Elevated serum creatinine and abdominal pain were also more frequent in pediatric-onset TAK (Fig. 2).

Angiographic extent of disease

As per Hata's angiographic classification [29], type IV disease was more frequent in pediatric-onset TAK,

whereas type I disease was more frequent in adult-onset TAK (Fig. 3). As per a recently proposed novel angiographic classification [30], there was no difference observed between pediatric-onset and adult-onset TAK (Supplementary Fig. 2). Considering individual vessels, aorta, splanchnic vessels overall, superior mesenteric artery, and renal arteries were more commonly involved in pediatric-onset TAK, whereas subclavian arteries were more commonly involved in adult-onset TAK (Supplementary Figures S3a, S3b, S3c).

Drug treatments received

Cyclophosphamide, overall biologic DMARDs, and tumor necrosis factor inhibitors were more frequently used in pediatric-onset than in adult-onset TAK. The use of corticosteroids and other conventional DMARDs was similar between pediatric-onset and adult-onset TAK (Fig. 4a).

Surgical or endovascular procedures

The overall use of surgical or endovascular procedures was similar between pediatric-onset and adult-onset TAK (Fig. 4b).

Study,	Single	Prospective	Defini-	Pedia	atric-onset TA	K		Adul	lt-onset TAK			Comparison	SI		
country [reference]	center/ multi center	or retro- spective	tion of pediatric- onset TAK	u	Age	Gender (F:M)	Delay to diagnosis	u u	Age	Gender (F:M)	Delay to diagnosis	Clinical profile	Angiogra- phy	Treatments	Outcomes
Cong 2010, China [21]	Single	Retrospec- tive	≤18 years	31	13.7 (6–18) y ^a	24:7	20 m ^b	94	NA	84:10	15.5 m ^b	>	>	×	×
Jales-Neto 2010, Brazil [22]	Single	Prospective	≤18 years	17	16 (1–18) y ^c	11:6	3 (0–22) y ^c	45	29 (21–53)°	40:5	3.5 (0-19) y ^c	>	>	>	>
Acschli- mann 2019, Canada [23]	Single	Retrospec- tive	≤18 years	29	10.8 (9.4– 13.1) y ^d	22:7	6 (3–13.2) m ^d	48	26.9 (22–36.3) y ^d	48:0	12.2 (4.5– 36.5) m ^d	>	>	>	>
Bolek 2021, Turkey [24]	Single	Retrospec- tive	<18 years	25	12.8 (4.6) y ^e	19:6	7.6 (16.8) ^d	154	35.7 (12.7) y ^e	142:12	4 (24.3) m ^d	>	>	>	>
Karabacak 2021, Turkey [25]	Multi	Retrospec- tive	<18 years	24	14 (9–15) y ^d	21:3	3 (1–10) m ^d	117	30 (24-43) y ^d	104:13	12 (5–58) m ^d	>	>	>	>
Danda 2021, India [26]	Single	Prospective and retro- spective	≤16 years	119	14 (11–15) y ^d	84:35	NA	483	26 (21–23) y ^d	382:101	NA	>	>	>	>
Cocchiara 2020, Italy [27]	Single	Retrospec- tive	<18 years	18	NA	15:3	5 m ^b	40	NA	31:9	10 m ^b	>	>	>	>
aMean (rang F female, <i>m</i>	ge); ^b median; ^c months, <i>M</i> m	median (range ale, <i>NA</i> not av	e); ^d median (ir ailable, y year	nterqu 's	artile range);	^e mean (sti	andard deviati	(uo							

		2	a Vascu	ar features			2b Car	diac features		2d Ne	eurological features		
	Pediatr	ic A	dult		Log Risk-Ratio	Weight	Pediatric Adult Study Yes No Yes No		Log Risk-Ratio Weight with 95% Cl (%)	Pediatric Adult Study Yes No Yes No	-	Log Risk-Ratio with 95% CI	Weight (%)
Study	Yes N	lo Ye	s No		with 95% CI	(%)	1 Dyspnea Cong 2010 7 94 19 70		0.16[-0.61, 0.941 10.21	1 Stroke/TIA		0.011.101.1	
01 Pulse loss/deficit							Aeschimann 2019 4 25 7 41		-0.06 [-1.19, 1.08] 6.68	Jales-Neto 2010 3 14 8 37 Aeschlimann 2019 3 26 3 45		-0.01 [-1.21, 1.20] 0.50 [-1.03, 2.04]	2.14
Cong 2010	16 1	15 73	21	-	-0.41 [-0.77, -0.05]	4.38	Danda 2021 28 80 121 326 Heterogeneity: 1 ² = 0.00, P = 0.00%, H ² = 1.00		-0.04 [-0.40, 0.31] 15.88 -0.01 [-0.32, 0.30]	Karabacak 2021 1 23 8 108		-0.50 [-2.54, 1.53]	0.81
Jales-Neto 2010	10	7 36	9	-	-0.31 [-0.73, 0.12]	3.94	Test of $\theta_i=\theta_i;$ G(2) = 0.24, $p=0.89$	•		Danda 2021 10 98 36 411	. 🛨	0.14 [-0.53, 0.81]	5.48
Aeschlimann 2019	17 1	12 34	14	-	-0.19 [-0.54, 0.17]	4.39	2 Palpitations			Heterogeneity: $\tau^{e} = 0.00$, $l^{e} = 0.00\%$, $H^{e} = 1.00$ Test of $R_{e} = R$: $O(3) = 0.85$, $p = 0.89$	•	0.11 [-0.42, 0.64]	
Danda 2021	73 3	35 342	105		-0.12 [-0.26, 0.02]	5.72	Cong 2010 1 30 10 84		-1.19 [-3.21, 0.82] 2.82	(earlor of - of, allo) - 0.00, p - 0.00			
Heterogeneity: $\tau^2 = 0.00$, $I^2 = 0.00$	10.35%, H	¹² = 1.12		•	-0.19 [-0.33, -0.05]		Test of $\theta_i = \theta_i$: $Q(0) = 0.00$, $p = .$		-1.19[-3.21, 0.82]	2 Syncope	_		
Test of $\theta_i = \theta_j$: Q(3) = 2.53, p =	= 0.47						3 Angina			Jales-Neto 2010 6 11 11 34		-0.63 [-1.78, 0.53] 0.37 [-0.46, 1.19]	4.03
							Cong 2010 0 31 9 85		-1.86 [-4.67, 0.96] 1.56	Aeschimann 2019 4 25 4 44		0.50 [-0.80, 1.81]	1.85
02 Vascular bruit				_			Aeschlimann 2019 2 27 2 46 Heterogeneity: t ² = 1.28, I ² = 46.00%, H ² = 1.85		- 0.50 [-1.40, 2.41] 3.10 -0.44 [-2.71, 1.83]	Karabacak 2021 3 21 11 105		0.28 [-0.92, 1.47]	2.16
Cong 2010	16 1	15 62	32	-	-0.25 [-0.62, 0.13]	4.29	Test of $\theta_i=\theta_j;$ Q(1) = 1.85, $p=0.17$			Danda 2021 9 99 57 390 Heterogeneity: 1 ² = 0.04, I ² = 13.37%, H ² = 1.1	15	-0.43 [-1.10, 0.25] -0.05 [-0.51, 0.41]	5.45
Jales-Neto 2010	10	7 23	22	-	0.14 [-0.35, 0.63]	3.53	4 Myocardial infarction			Test of $\theta_i = \theta_i$: Q(4) = 4.11, p = 0.39	•	0.001 0.011 0.011	
Aeschlimann 2019	17 1	12 29	9 19	-	-0.03 [-0.41, 0.35]	4.22	Jales-Neto 2010 1 16 5 40 Ascelutarea 2019 2 27 2 46		-0.64 [-2.71, 1.44] 2.69				
Danda 2021	55 5	53 251	196		-0.10 [-0.30, 0.10]	5.40	Heterogeneity: t ² = 0.00, P = 0.00%, H ² = 1.00	-	-0.02 [-1.42, 1.38]	3 Headache Cong 2010 11 20 21 73		0.461-0.14 1.07	6.25
Heterogeneity: $\tau^2 = 0.00$, $l^2 = 0.00$	0.00%, H ²	= 1.00		•	-0.09 [-0.24, 0.06]		Test of $\theta_i=\theta_j;Q(1)=0.63,p=0.43$			Jales-Neto 2010 8 9 24 21	-	-0.13 [-0.70, 0.45]	6.70
Test of $\theta_i = \theta_j$: Q(3) = 1.63, p =	= 0.65						5 Chest pain			Aeschimann 2019 11 18 10 38		0.60 [-0.12, 1.32]	4.91
							Aeschlimann 2019 3 26 11 37 Danda 2021 11 97 57 390	-	-0.80 [-1.99, 0.40] 6.30 -0.22 [-0.84, 0.39] 12.30	Karabacak 2021 10 14 30 86		0.48 [-0.09, 1.04]	6.83
03 BP asymmetry				_			Heterogeneity: $\tau^{\rm p}$ = 0.00, P = 0.00%, $H^{\rm p}$ = 1.00	•	-0.34 [-0.89, 0.20]	Cocchiara 2020 5 13 2 38		1.71 [0.17, 3.26]	1.37
Cong 2010	8 2	23 34	60		-0.34 [-0.99, 0.32]	2.66	Test of $\theta_i = \theta_i$: $Q(1) = 0.70$, $p = 0.40$			Heterogeneity: $\tau^2=0.01,l^2=9.40\%,H^2=1.10$	ı 🔶	0.45 [0.22, 0.69]	
Jales-Neto 2010	11	6 34	11		-0.16 [-0.54, 0.23]	4.17	6 LVH	_		Test of $\theta_i = \theta_j;$ Q(5) = 7.02, $p = 0.22$			
Aeschlimann 2019	20	3 31	16		0.28 [0.02, 0.54]	5.04	Cong 2010 6 25 23 71 Heterogeneity: t ² = 0.00, P = .%, H ² = .		-0.23 [-1.04, 0.57] 9.87 -0.23 [-1.04, 0.57]	4 Dizziness			
Cocchiara 2020	4 1	14 5	35		- 0.58 [-0.62, 1.77]	1.16	Test of $\theta_i = \theta_j; \mathbf{Q}(0) = -0.00, \mathbf{p} = .$	-		Cong 2010 13 18 50 44		-0.24 [-0.69, 0.22]	8.71
Heterogeneity: $\tau^2 = 0.05$, $l^2 = 4$	47.34%, H	r = 1.90	,		0.05[-0.29, 0.38]		7 Aortic regurgitation			Jales-Neto 2010 5 12 16 29		-0.19 [-1.02, 0.65]	3.94
Test of $\theta_i = \theta_j$: Q(3) = 5.75, p =	= 0.12						Danda 2021 3 105 37 410 Heterogeneih: 1 ⁴ = 0.00. I ⁴ = .%. H ⁴ =	-	-1.09 [-2.25, 0.07] 6.53 -1.09 [-2.25, 0.07]	Aeschimann 2019 5 24 4 44 Heteroneneity: x2 = 0.00 E = 0.00 ^e H ² = 1.00		0.73 [-0.50, 1.96]	2.06
04 Humantanaian							Test of $\theta_i = \theta_i$: $\Omega(0) = 0.00$, $p = .$	-	The Farmer angul	Test of $\theta_i = \theta_i$: Q(2) = 2.09, p = 0.35	•	0.14[-0.52, 0.24]	
Cons 2010	22	0	25	-	0.171.000 0.17	5.04	8 Cardiomyopathy						
Joing 2010	23	0 59	35		0.001 0.10 0.43]	0.04	Danda 2021 18 90 26 421	±	1.05 [0.49, 1.62] 12.95	5 Visual disturbance	_	.0.341.0.00.0.00	5.64
Jales-Iveto 2010	11	6 ZZ	23		0.28 [-0.18, 0.74]	3.70	Heterogeneity: $\tau^{2} = 0.00$, $P = .%$, $H^{2} = .$ Test of $\theta_{-} = \theta_{-} Q(0) = 0.00$, $p = .$	•	1.05 [0.49, 1.62]	Jales-Neto 2010 5 12 9 36	_	0.39 [-0.55, 1.33]	3.26
Aeschlimann 2019	1/ 1	12 15	33		0.63 [0.11, 1.15]	3.35	O Marcal follows			Danda 2021 14 94 34 413	-	0.53 [-0.05, 1.12]	6.52
Karabacak 2021	13	11 22	94		1.05 [0.52, 1.58]	3.31	Jales-Neto 2010 3 14 7 38		0.13 [-1.11, 1.36] 6.02	Heterogeneity: $\tau^2 = 0.13$, $l^2 = 50.00\%$, $H^2 = 2.0$	e e	0.18 [-0.40, 0.76]	l.
Heterogeneity: $\tau^2 = 0.11$, $t^2 = 0.11$	9.56%, H	* = 3.28		•	0.49[0.10, 0.88]		Heterogeneity: $\tau^2 = 0.00$, $F = .%, H^2 = .$	-	0.13 [-1.11, 1.36]	Test of $\theta_i = \theta_j$: Q(2) = 3.98, p = 0.14			
lest of $\theta_i = \theta_j$: Q(3) = 9.85, p =	= 0.02						Hear or 0, = 0,: Li(u) = 0.00, p = .			6 Retinopathy			
05 Systelia hyportension							Overall	•	-0.07 [-0.44, 0.30]	Cong 2010 5 26 15 79		0.01 [-0.92, 0.94]	3.34
Danda 2021	70 5	0 234	213		033[019_048]	5 70	Test of $\theta_i = \theta_i$: Q(13) = 23.55, p = 0.04			Heterogeneity: $\tau^2 = 0.00$, $P = .%$, $H^2 = .$ Test of $\theta = \theta : O(0) = 0.00$, $\eta =$	-	0.01 [-0.92, 0.94]	
Hotorogeneity: $\tau^2 = 0.00$ $l^2 =$	% ⊌2_	10 2.04	210	T	0.33[0.10, 0.40]	0.70	Test of group differences: $\boldsymbol{Q}_{g}(\boldsymbol{\delta})=20.19,p=0.01$		-	rear or of - of an of - or out b - r			
Test of $\beta = \beta_1 O(0) = 0.00, r^2 = 0.00$. 70, H ^s = .			•	0.33 [0.19, 0.46]		Bandom-effects REML model Favours adult-o	nset TÅK 👉 🗖 🔜 2	Favours pediatric-onset TAK	7 Ocular symptoms			
$reat or o_i = o_j, o_i(o) = -0.00, p$							2c Consti	tutional features		Aeschimann 2019 5 24 6 42 Heterogeneity: x2 = 0.00 12 = % H2 =	-	0.32 [-0.77, 1.42]	2.53
06 Diastolic hypertension							Pediatric Adult Pediatric Adult	tutional reatures	Log Risk-Ratio Weight	Test of $\theta_1 = \theta_1$: $Q(0) = -0.00$, $p = .$	· · · · ·	electronic, the	
Danda 2021	52 5	6 188	259		0.14 [-0.09. 0.36]	5.27	1 Constitutional		With 30% C1 (%)				
Heterogeneity; $\tau^2 = 0.00$, $l^2 =$.%. H ² = .				0.14 [-0.09. 0.36]		Cong 2010 7 24 41 53	+	-0.66 [-1.35, 0.03] 5.88	8 Seizure Asschlimann 2019 2 27 1 47		1 20 [-1 16 3 55]	0.61
Test of $\theta = \theta$; $Q(0) = 0.00$, p =				Y .	,		Heterogeneity: t ² = 0.00, l ² = .%, H ² = . Test of 0. = 0; Q(0) = 0.00, p = .	-	-0.66 [-1.35, 0.03]	Heterogeneity: x ² = 0.00, l ² = .%, H ² = .		1.20 [-1.16, 3.55]	i 0.01
										Test of $\theta_i=\theta_j; \mathbf{G}(0)=0.00, p=.$			
07 Claudication							2 Arthralgias/arthritis Cong 2010 2 29 9 85		-0.39(-1.87, 1.08) 2.21	0			
Cong 2010	13 1	18 42	52	-	-0.06 [-0.53, 0.41]	3.64	Jales-Neto 2010 7 10 23 22		-0.22 [-0.85, 0.42] 6.33	Heterogeneity: τ ² = 0.05, I ² = 26.34%, H ² = 1.3	36	0.20[0.02, 0.39]	
Jales-Neto 2010	10	7 37	8	-	-0.33 [-0.76, 0.09]	3.96	Aeschlimann 2019 2 27 14 34 Heteropeneity: r ² = 0.09 F = 20 23%, H ² = 1.25		-1.44 [-2.85, -0.03] 2.39 -0.49 [-1.17 0.19]	Test of $\theta_i = \theta_j$: Q(23) = 28.68, p = 0.19			
Aeschlimann 2019	6 2	23 22	26		-0.80 [-1.57, -0.02]	2.16	Test of 0, = 0; Q(2) = 2.42, p = 0.30	•	,,	Test of group differences: $Q_0(7) = 9.46$, $p = 0.2$	/2	_	
Danda 2021	46 6	52 264	183		-0.33 [-0.56, -0.09]	5.22	3 Fever			Favours adult-or	nset TAK	4 ours pediatric-onset TAM	ĸ
Heterogeneity: $\tau^2 = 0.00$, $I^2 = 0$	0.00%, H ²	= 1.00		•	-0.31 [-0.50, -0.13]		Cong 2010 5 26 17 77		-0.11 [-1.03, 0.80] 4.38	Random-effects REML model	· · · · · ·		
Test of $\theta_i = \theta_i$: Q(3) = 2.58, p =	= 0.46			'			Jales-Neto 2010 7 10 10 35 Assochimano 2010 5 24 5 42	-	0.62[-0.17, 1.41] 5.16	Pediatric	e Other features	Log Biek-B	latio Weight
							Karabacak 2021 6 18 16 95		0.55 [-0.28, 1.38] 4.89	Study Yes No	Yes No	with 95%	CI (%)
08 UL claudication							Danda 2021 35 73 84 363	•	0.54 [0.21, 0.88] 9.13	1 Elevated serum creatinine			
Aeschlimann 2019	1 2	28 20	28		-2.49 [-4.45, -0.54]	0.49	Gocchiara 2020 10 8 7 33 Heterogeneity: τ ² = 0.00, I ² = 0.00%, H ² = 1.00	•	0.56 [0.31, 0.82]	Aeschlimann 2019 2 22 Danda 2021 19 89	1 32	1.01 [-1.33, 3	3.35] 4.24
Karabacak 2021	5 1	19 72	44		-1.09 [-1.88, -0.30]	2.10	Test of $\theta_i=\theta_i$: Q(5) = 4.33, p = 0.50	•		Heterogeneity: T ² = 0.00, I ² = 0.00%, H ² = 1.00		1.22 [0.66, 1	1.77]
Cocchiara 2020	1 1	17 12	28		-1.69 [-3.65, 0.28]	0.48	4 Malaise/fatigue			Test of $\theta_i=\theta_j;Q(1)=0.03,p=0.86$			
Heterogeneity: $\tau^2=0.06,\ I^2=1$	8.85%, H ²	= 1.10		-	-1.39 [-2.16, -0.61]		Cong 2010 5 28 27 67		-0.58 [-1.44, 0.29] 4.67	2 Pulmonary involvement			
Test of $\theta_i = \theta_j$: Q(2) = 1.83, p =	= 0.40			•			Aeschimann 2019 14 15 21 27 Danda 2021 40 68 152 295		0.10[-0.40, 0.59] 7.60 0.09[-0.19, 0.36] 9.63	Jales-Neto 2010 2 15	4 41	0.28 [-1.32,	1.88] 8.04
							Heterogeneity: $\tau^{\rm c}$ = 0.00, ${\rm P}$ = 0.00%, ${\rm H}^{\rm c}$ = 1.00		0.04 [-0.19, 0.27]	Heterogeneity: $\tau^2 = 0.00$, $P = .%$, $H^2 = .$ Test of $\theta = \theta$: $Q(0) = 0.00$, $n = .$		0.28 [-1.32, 1	1.88]
09 LL claudication							Test of $\theta_i = \theta_j; Q(2) = 2.12, p = 0.35$						
Aeschlimann 2019	5 2	24 6	42		0.32 [-0.77, 1.42]	1.32	5 Night sweats			3 Abdominal pain	7 38	0641-027	1.641 16.61
Karabacak 2021	5 2	24 18	98	-	0.11 [-0.80, 1.01]	1.76	Cong 2010 1 30 4 90		-0.28 [-2.43, 1.88] 1.17	Danda 2021 5 12	27 420 -	0.69 [0.06, 1	1.32] 24.34
Heterogeneity: $\tau^2 = 0.00$, $I^2 = 0$	0.00%, H ²	= 1.00		•	0.19 [-0.50, 0.89]		Heterogeneity: t ² = 0.00, l ² = 0.00%, H ² = 1.00	-	-0.70 [-2.20, 0.80]	Heterogeneity: τ^{2} = 0.00, I^{2} = 0.00%, H^{2} = 1.00	•	0.67 [0.14,	1.21]
Test of $\theta_i = \theta_j$: Q(1) = 0.09, p =	= 0.77			•			Test of $\theta_i = \theta_j; Q(1) = 0.29, p = 0.59$			test of $\theta_i = \theta_j; \ \text{Q}(1) = 0.01, \ p = 0.93$			
							6 Weight loss			4 Ischemic abdominal pain			
10 Carotidodynia							Cong 2010 0 31 3 94		-0.83[-3.76, 2.11] 0.66	Aeschlimann 2019 2 27 Heteropopultur 2 - 0.00 R - 55 HR -	0 48	2.10 [-0.90, 5	3.10] 2.70
Jales-Neto 2010	3 1	14 9	36		-0.13[-1.31, 1.06]	1.17	Aeschimann 2019 8 21 7 41	-	0.64 [-0.27, 1.54] 4.43	Test of $\theta_i = \theta_i$: Q(0) = -0.00, p = .			
Aeschlimann 2019	1 2	28 8	3 40		-1.58 [-3.60, 0.45]	0.46	Karabacak 2021 10 14 28 84		0.51 [-0.06, 1.08] 6.89	E Non-specific abdominal pain			
Karabacak 2021	0 2	24 19	97		-2.12 [-4.89, 0.65]	0.25	Uanda 2021 12 95 65 382 Heterogeneity: τ ² = 0.14, I ² = 49.11%, H ² = 1.97		-0.27 [-0.85, 0.31] 6.83 0.36 [-0.13, 0.84]	Aeschlimann 2019 4 25	3 45 —	0.79 [-0.63, 2	2.22] 9.65
Danda 2021	5 10	03 29	418		-0.34 [-1.26, 0.59]	1.70	Test of $\theta_i=\theta_i$: Q(4) = 7.61, p = 0.11	•		Heterogeneity: $\tau^{\rm p}$ = 0.00, ${\rm P}$ = .%, ${\rm H}^{\rm p}$ = .	-	0.79 [-0.63, 2	2.22]
Heterogeneity: $\tau^2 = 0.00$, $I^2 = 0$	0.00%, H ²	= 1.00			-0.51 [-1.17, 0.16]		7 Lymphadenopathy			Test of $\theta_{i}=\theta_{j};$ Q(0) = -0.00, p = .			
Test of $\theta_i = \theta_j$: Q(3) = 2.90, p =	= 0.41						Aeschimann 2019 3 26 2 46		0.91 [-0.82, 2.64] 1.71	6 Cutaneous features			
				4			Heterogeneity: $\tau^2 = 0.00$, $P = .%$, $H^2 = .$ Test of $\theta = \theta \cdot O(0) = 0.00$, $\rho = -$	-	0.91 [-0.82, 2.64]	Aeschlimann 2019 2 27	11 37	-1.20 [-2.64, 0	0.23] 9.55
Overall				•	-0.06 [-0.20, 0.08]		reasons $v_i \equiv a_j$; $u_i(u) \equiv u_i(u)$, $p \equiv .$			Heterogeneity: $\tau^2 = 0.00$, $P = .%$, $H^2 = .$ Test of $\theta_i = \theta_i$: $Q(0) = 0.00$, $p = .$	-	-1.20 [-2.64, 0	1.23]
Heterogeneity: $\tau^2 = 0.09$, $l^2 = 1$	73.18%, H	¹² = 3.73					Overall	+	0.16 [-0.08, 0.41]				
Test of $\theta_i = \theta_j$: Q(30) = 102.84	, p = 0.00						reserogeneity: t ⁺ = 0.14, I ² = 54.83%, H ² = 2.21 Test of 0, = 0; Q(20) = 40.33, p = 0.00			Overall	•	0.67[0.16,	1.18]
Test of group differences: Q _b (S	9) = 62.96	p = 0.0	0				Test of group differences: Q ₆ (6) = 22.07, p = 0.00			Test of 0, = 0; Q(7) = 11.02, p = 0.14			
			-6	-4 -2 0	2		Product allock DEM as 11	-4 -2 0	2	Test of group differences: Q ₅ (5) = 10.98, p = 0.1	05		
Random-effects REML model			Favours	adult-onset TAK	Favours pediatric-onset TA	ĸ	nanoom-effects HEML model Favours adult-	onset TAK	Favours pediatric-onset TAK	Device of the Data to Favore white	-2 0 2 4	6 wours pediatric onset T	AK

Fig. 2 Comparison of clinical features at presentation between pediatric-onset and adult-onset Takayasu arteritis. a Vascular features, b cardiac features, c constitutional features, d neurological features, e other features

Outcomes

The proportion of patients attaining remission (Fig. 4c) and mortality (Fig. 4d) were similar between pediatric-onset and adult-onset TAK. Outcomes that could not be pooled across studies are presented in Table 2. Aeschlimann et al. [23] reported remission at 6 months in a significantly lesser proportion of pediatric-onset than in adult-onset TAK. Karabacak et al. [25] reported greater damage assessed using the Vasculitis Damage Index in patients with adult-onset TAK than in pediatric-onset TAK.

Subgroup analyses

Excluding studies that were retrospective (Jales-Neto 2010) or both prospective and retrospective (Danda 2021), subgroup analyses were conducted for retrospective studies alone. Comparing with associations observed

Fig. 3 Comparison of angiographic subtypes (Hata's) between pediatric-onset and adult-onset Takayasu arteritis

Study	Pediatric Yes No	c Ad Yes	dult No		Log Risk-Ratio with 95% Cl	Weight (%)
1 Type I				_		
Cong 2010	6 25	5 44	50	-	-0.88 [-1.63, -0.13	4.46
Jales-Neto 2010	3 14	13	32		-0.49 [-1.62, 0.63	2.98
Bolek 2021	1 24	33	121		-1.68 [-3.62, 0.27	1.37
Karabacak 2021	1 23	3 42	75		-2.15 [-4.09, -0.22	1.38
Danda 2021	6 110	106	363	-	-1.47 [-2.27, -0.68	4.24
Heterogeneity: $\tau^2 = 0$.00, $I^2 = 0$.	00%, I	$H^2 = 1.00$	•	-1.13 [-1.60, -0.67	I
Test of $\theta_i = \theta_j$: Q(4) =	3.75, p =	0.44				
2 Type II	2 00		80	-		0.01
Lolog Noto 2010	3 28	5 5	42		0.80 [-0.77, 1.97	2.31
Balak 2001	6 10) 21	40		0.28 [-2.05, 2.02	1.00
Bolek 2021		1 14	123		0.18[-0.59, 0.94	4.39
Narabacak 2021	3 21	14	103		0.04[-1.12, 1.21	2.85
Danda 2021	5 111	24	445		-0.17[-1.11, 0.77	3.63
Test of $\theta_i = \theta_j$: Q(4) =	.00, 1² = 0. 0.89, p =	00%, i 0.93	1² = 1.00	•	0.12[-0.36, 0.60	
3 Type III				_		
Cong 2010	2 29	, 1 , -	93		1.80 [-0.56, 4.17	0.98
Jales-Neto 2010	1 16	> 2	43		0.28 [-2.05, 2.62	1.00
DUIEK 2021	1 24	+ 6	148		0.03 [-2.05, 2.10	1.23
Narabacak 2021	4 20	, 0	117		3.75 0.86, 6.64	0.69
Danda 2021	6 110	23	446		0.05 [-0.82, 0.93	3.90
Heterogeneity: $\tau^2 = 0$ Test of $\theta_i = \theta_j$: Q(4) =	.66, l ² = 4 ⁻ 7.23, p =	1.42%, 0.12	H ² = 1.71	•	0.79 [-0.34, 1.91	
4 Type IV						
Cong 2010	10 21	16	78		0.64 [-0.04 1.32	4.81
Jales-Neto 2010	2 15	5 2	43	_	0.97 [-0.91, 2.85	1.44
Bolek 2021	2 23	3 2	152		1.82 [-0.10 3.73	1.40
Karabacak 2021	5 10	. 2	114		2.09 [0.73. 3.46	2.33
Danda 2021	29 87	, 3 7 67	402		0.56 0 17 0 94	6.30
Heterogeneity: T ² – 0	13 l ² = 3	8.66%	$H^2 = 1.63$	T	0.89 [0.35 1.42	. 0.00
Test of $\theta_i = \theta_j$: Q(4) =	5.96, p =	0.20		•	0.00 [0.00, 1.42	•
5 Type V						
Cong 2010	10 21	28	66	=	0.08 [-0.52, 0.68	5.22
Jales-Neto 2010	10 7	26	19		0.02 [-0.45, 0.49	5.88
Bolek 2021	14 11	82	72		0.05 [-0.33, 0.43	6.34
Karabacak 2021	11 13	58	59		-0.08 [-0.55, 0.39	5.87
Danda 2021	61 55	5 223	246		0.10 [-0.10, 0.30	7.07
Heterogeneity: $\tau^2 = 0$ Test of $\theta_i = \theta_i$: Q(4) =	.00, l² = 0. 0.53, p =	.00%, H 0.97	H ² = 1.00		0.06 [-0.08, 0.21	l
6 C+						
Aeschlimann 2019	3 22	2 5	43		0.14 [-1.21. 1.49	2.37
Danda 2021	6 110) 53	416	-	-0.78 [-1.60 0.04	4.14
Heterogeneity: $\tau^2 = 0$ Test of $\theta_i = \theta_j$: Q(1) =	.10, l² = 24 1.32, p =	4.02%, 0.25	H ² = 1.32	•	-0.48 [-1.33, 0.37	
7 P+						
Aeschlimann 2019	4 21	5	43		0.43 [-0.79. 1.65	2.69
Bolek 2021	5 20) 24	130	-	0.25 [-0.62. 1.12	3.94
Danda 2021	5 111	37	432	-	-0.60 [-1.52 0.31	3.75
Heterogeneity: $\tau^2 = 0$.07, l ² = 2	1.75%	H ² = 1.28		-0.02 [-0.66. 0.61	
Test of $\theta_i = \theta_j$: Q(2) =	2.47, p =	0.29	= 1.20	•		
Overall				•	0.03 [-0.22, 0.29	I
Heterogeneity: $\tau^2 = 0$.22, l² = 63	3.54%,	H ² = 2.74	,		
Test of $\theta_i = \theta_i$: Q(29)	= 67.81, p	= 0.00	1			
Test of group differen	ices: Q _b (6)	= 37.5	8, p = 0.00		_	
andom-effects REM	model			-5 0 5	10	
	adult of	aco+ 7		<u>`</u>	Favours nodiate	-0060+ TA
Favours	adult-0	iset I			ravours pediatri	-onset IA

4a Immur	IOSL	ıpp	ore	ssive	e treatments use	d						4b ۱	/ascul	ar int	erven	tions				
Pe Study Ye	diatri s N	ic o Y	Adu Yes	ult No		Log Risk-Ratio with 95% Cl	Weight (%)	Study	F	Pedia Yes	atric No	Ad Yes	ult No				Log R with	isk-Ratio 95% CI	Weigh (%)	t
01 Corticosteroids								Any vascular intervent	tion											_
Jales-Neto 2010 13		4	30	15	-	0.14 [-0.20, 0.47]	4.75	Jalas Nata 0010		~	•	17	00				0.041	0.05 0.001	01 00	
Bolek 2021 25		0 1	154	0		-0.02 [-0.07, 0.04]	5.25	Jales-Neto 2010		9	8	17	28				0.34 [-0	J.25, U.92J	21.23	
Karabacak 2021 24		01	107	10		0.07 [-0.01, 0.15]	5.23	Aeschlimann 2019		6	23	12	36				-0.19 [-1	1.05, 0.68]	19.17	
Danda 2021 83 Cocchiara 2020 5	2	3	18	91		0.05 [-0.06, 0.16]	3.19	Bolek 2021		5	20	27	127		_	-	0.13 [-0	0.72, 0.99]	19.25	
Heterogeneity: $\tau^2 = 0.00$, $l^2 = 30.68\%$, $H^2 = 1.44$		0			_	0.03 [-0.03, 0.09]	0.10	Karabacak 2021		9	15	4	113				2.40 [1	1.30. 3.491	17.33	
Test of $\theta_i = \theta_i$: Q(4) = 5.61, p = 0.23								Danda 2021	4	-	110	253	220			_	-0.38[-0	0.60 -0.171	23.03	
												200	200				-0.00[-0		20.00	
02 Methotrexate						0.407.045.4.07	0.00	Heterogeneity: $\tau^2 = 0.90$,	$I^2 = 90$.51%	5, H ² =	= 10.5	3		<		0.39[-0	0.51, 1.28]		
Jales-Neto 2010 9 Bolek 2021 16		9	15	30 67		0.46[-0.15, 1.07]	3.66	Test of $\theta_i = \theta_j$: Q(4) = 28.	8.40, p =	0.00)									
Karabacak 2021 12	1	2	76	38		-0.29 [-0.71, 0.13]	4.50													
Danda 2021 15	8	9	31	345	-	0.56 [-0.02, 1.14]	3.99	Overall							<		0.39[-0	0.51. 1.281		
Heterogeneity: $\tau^{z}=0.08,l^{z}=59.57\%,H^{z}=2.47$					•	0.17 [-0.20, 0.53]			12 - 00	E10/	Ц2	10 5	0				0.001			
Test of $\theta_i = \theta_j$: Q(3) = 7.05, p = 0.07								Helefogeneity: $t^2 = 0.90$,), i ² = 90.	.51%	o, ⊓- =	= 10.5	3							
03 Azathioprine								Test of $\theta_i = \theta_j$: Q(4) = 28.	8.40, p =	0.00)									
Jales-Neto 2010 5	1	2	10	35		0.28 [-0.64, 1.20]	2.91	Test of aroun differences	s· O (0) ;	= 0 0)0 n :	-								
Bolek 2021 7	1	8	49	105		-0.13 [-0.80, 0.54]	3.68	feet of group differences	o. a _b (o) -	- 0.0	, p -	••					<u>۲</u>			
Karabacak 2021 21		3	79	35		0.23 [0.04, 0.43]	5.08							-2	0	2	4			
Danda 2021 17	8	7	68	308	-	-0.10 [-0.59, 0.38]	4.29	Random-effects REML mo	odel			Favours	adult-onset			Favours pediate	ic-onset TAK			
Heterogeneity: $\tau^2 = 0.01$, $l^2 = 13.42\%$, $H^2 = 1.15$					•	0.14 [-0.08, 0.36]							4	c Rem	issio	า				
Test of $\theta_i = \theta_j$: Q(3) = 2.42, p = 0.49												Pe	diatric	Ad	ult			Loa Risk	-Ratio	Weiaht
04 MMF								Study				Ye	s No	Yes	No			with 95	% CI	(%)
Jales-Neto 2010 5	1	2	9	36		0.39 [-0.55, 1.33]	2.84	Demission of emulaities				10		100					/0 0.	(/0)
Danda 2021 58	4	6 2	241	135		-0.14 [-0.33, 0.05]	5.09	Remission at any visit o	or last to	niow	-up									
Heterogeneity: $\tau^2 = 0.02$, $l^2 = 13.16\%$, $H^2 = 1.15$					•	-0.09 [-0.39, 0.22]		Jales-Neto 2010				4	13	25	20			-0.86 [-1.7	5, 0.04]	8.92
lest of $\theta_i = \theta_j$: Q(1) = 1.15, p = 0.28								Aeschlimann 2019				18	9	36	12			-0.12 [-0.4	3, 0.19]	23.88
05 Leflunomide								Karabacak 2021				12	12	92	22			-0.48 [-0.8	9, -0.07]	20.46
Bolek 2021 3	2	2	8	146		0.84 [-0.42, 2.10]	2.09	Danda 2021				74	3	245	42			0.12 0.0	5, 0.18]	30.71
Karabacak 2021 3	2	1	35	79	-	-0.90 [-1.99, 0.20]	2.45	Cocchiara 2020				8	10	29	11			-0.49 [-1.0	4. 0.061	16.04
Heterogeneity: $\tau^2 = 1.14$, $l^2 = 75.99\%$, $H^2 = 4.17$						-0.06 [-1.76, 1.64]		Heterogeneity: T ² – 0.08	l² - 75 9	3%	H2 – 4	15						-0.24 [-0.5	3 0 071	
Test of $\theta_i = \theta_j$: Q(1) = 4.17, p = 0.04									1 = 70.5	3 /8,	11 4	.15						-0.24 [-0.5	5, 0.07]	
06 Cyclophosphamide/ Chlorambucil								Test of $\theta_i = \theta_j$: $Q(4) = 18.3$	31, p = 0.	.00										
Jales-Neto 2010 1	1	6	2	43		0.28 [-2.05, 2.62]	0.84										-			
Heterogeneity: τ^2 = 0.00, I^2 = .%, H^2 = .						0.28 [-2.05, 2.62]		Overall										-0.24 [-0.5	5, 0.07]	
Test of $\theta_i = \theta_j$: Q(0) = 0.00, p = .								Heterogeneity: τ ² = 0.08, I	$l^2 = 75.93$	3%,	$H^2 = 4$.15								
07 Cyclophosphamide								Test of $\theta_i = \theta_i$: Q(4) = 18.3	31, p = 0.	.00										
Bolek 2021 15	1	0	51	103		0.59 [0.20, 0.99]	4.59	Test of group differences:	0 (0) -	0 00	n -									
Karabacak 2021 12	1	2	10	104	-	1.74 [1.03, 2.45]	3.53	lest of group differences.	$G_{b}(0) = 0$	0.00	, p = .				5					
Heterogeneity: τ^2 = 0.57, I^2 = 86.86%, H^2 = 7.61					-	1.13 [0.01, 2.25]									-2	Favours adult-onset TAK	°	Favours	ediatric-ons	at TAK
Test of $\theta_i = \theta_j$: Q(1) = 7.61, p = 0.01								Random-effects REML mod	del											
08 Biologic DMARDs								P	Pediatr	ric	Αd	ult		4d Mo	ortali	t y	l og	Risk-Rat	in W	eiaht
Bolek 2021 17		8	37	117		1.04 [0.65, 1.43]	4.59		Vee N		Vee	Na					209			(0/)
Karabacak 2021 10	1	4	16	98		1.09 [0.43, 1.74]	3.72	Study	tes in	10	res	INO					wit	n 95% C		(%)
Heterogeneity: $\tau^2 = 0.00, \ I^2 = 0.00\%, \ H^2 = 1.00$					•	1.05 [0.72, 1.39]		Mortality												
Test of $\theta_i = \theta_j$: Q(1) = 0.02, p = 0.90								Jales-Neto 2010	2 1	5	4	41				_	0.28	[-1.32, 1.8	381 3	7.35
09 TNFI								Acachlimann 2010	0 0	-	0	40					- 0.10	[0.00 E	01 1	0.65
Bolek 2021 12	1	3	15	139		1.59 [0.96, 2.23]	3.81	Aeschiimann 2019	2 2	./	0	40					2.10	[-0.90, 5.	oj i	0.05
Danda 2021 0	10	4	1	375		0.18 [-3.01, 3.37]	0.49	Bolek 2021	2 2	3	6	148					0.72	[-0.82, 2.2	26] 4	0.29
Heterogeneity: τ^{2} = 0.00, I^{2} = 0.00%, H^{2} = 1.00					•	1.54 [0.92, 2.16]		Karabacak 2021	0 2	4	5	108		-			-0.88	[-3.74, 1.9	98] 1	1.71
Test of $\theta_i = \theta_i$: Q(1) = 0.73, p = 0.39								Heterogeneity: $\tau^2 = 0.0$	$00. I^2 = 0$	0.009	%. H ²	= 1.0	0			-	0.52	[-0.46, 1.4	191	
10 Tocilizumab								The function $O(2) = 0$	10	0.5	-, · ·		-			· ·		,	,	
Bolek 2021 10	1	5	28	126		0.79 [0.20, 1.37]	3.96	$\log(0) = \sigma_j \cdot Q(3) = 2.$		0.5	5									
Karabacak 2021 7	1	7	4	110		2.12 [0.97, 3.26]	2.32													
Danda 2021 6	9	8	19	357		0.13 [-0.76, 1.02]	2.98	Overall								-	0.52	[-0.46, 1.4	19]	
Heterogeneity: $\tau^2 = 0.65$, $l^2 = 77.69\%$, $H^2 = 4.48$					-	0.95 [-0.09, 2.00]		Heterogeneity: $\tau^2 = 0.0$	$00, I^2 = 0$	0.009	%, H ²	= 1.0	0							
r_{00} or $\sigma_i = \sigma_j$, $c_{0}(z) = 7.21$, $p = 0.03$								Test of $A = A \cdot O(3) = 3$		0 5	5									
Overall					•	0.37 [0.13, 0.60]		$rest or \sigma_i = \sigma_j, \omega(3) = 2.$, p =	0.0	5									
Heterogeneity: $\tau^{2}=0.27,l^{2}=95.09\%,H^{2}=20.3$	7				•			Test of group difference	es: Q _h (0)) = C	0.00,	p = .								
Test of $\theta_i=\theta_j;$ Q(26) = 133.46, $p=0.00$														-5		0	5			
Test of group differences: $Q_{\rm b}(9)=64.49,p=0.0$	0			_				-						-0		0	5			
-				-4	-2 0 2	4		Random-effects REML n	model				Favours a	dult-onset	так 🔶	Favou	s pediatric-onset	TAK		

Fig. 4 Comparison of treatments and outcomes between pediatric-onset and adult-onset Takayasu arteritis. **a** Immunosuppressive treatments used, **b** vascular interventions, **c** remission at any visit or at last follow-up visit, **d** mortality

during primary analyses, claudication and elevated serum creatinine were no more different between pediatriconset and adult-onset TAK, carotidodynia was more frequent in adult-onset TAK, and weight loss was more frequent in pediatric-onset TAK (Supplementary Figure S4a, S4b, S4c, S4d). These secondary analyses could not be performed for neurological features since the data did not permit meta-analysis. Hata's type I disease continued to be more frequent in adults and type IV disease in children (Supplementary Figure S5). Comparing the involvement of individual vessels, aorta, splanchnic vessels overall and renal arteries (as on primary analyses) and celiac artery involvement (from a single study) were more frequently involved in pediatric-onset TAK. Subclavian artery involvement continued to be more frequent in adult-onset TAK (Supplementary Figure S6). Cyclophosphamide, overall biologic DMARDs, tumor necrosis factor inhibitors (as noted before), and additionally tocilizumab were more frequently used in pediatric-onset than in adult-onset TAK (Supplementary Figure S7a). Unlike in the primary analysis, remission was more frequently noted in adult-onset TAK than in pediatric-onset TAK (Supplementary Figure S7c). Other outcomes did not differ (Supplementary Figure S7b, S7d).

Study [reference]	Outcome	Pediatric-onset TAK	Adult-onset TAK	Inter-group difference*
Jales-Neto 2010 [22]	Relapse	4/17	8/45	1.32 (0.46–3.83)
	Procedural complications	4/17	3/45	3.53 (0.88–14.1)
Aeschlimann 2019 [23]	Remission at 6 months	11/24	29/39	0.62 (0.38-0.99)
	Angiographic stabilization at 6 months	5/8	8/17	1.33 (0.64–2.77)
	Relapse within 12 months	11/28	13/47	1.42 (0.74–2.73)
	VDI at last visit ^a	4 (3–6) ^b	2 (2–3) ^c	_**
Karabacak 2021 [25]	Relapse	8/12	42/94	1.49 (0.94–2.36)
	VDI at last visit ^a	4 (2–5)	5 (3–7)	0.017
	TADS at last visit ^a	8 (4–12)	8 (6–10)	0.919
	Angiographic stabilization at last visit	14/21	62/87	0.94 (0.67–1.30)
Danda 2021 [26]	Relapse	20/67	50/190	1.13 (0.73–1.76)

Table 2 Outcomes for which meta-analyses were not undertaken

^{*}Risk ratio pediatric-onset to adult-onset TAK (95% confidence intervals) for categorical outcomes; p value for Mann–Whitney U test for median with interquartile range

**Could not be compared as these were two different measures

^aMedian (IQR); ^bpediatric VDI; ^cadult VDI

TADS Takayasu arteritis damage score, TAK Takayasu arteritis, VDI Vasculitis Damage Index

Discussion

Overall, few studies of moderate to high quality had compared pediatric-onset with adult-onset TAK. Both pediatric-onset and adult-onset TAK were more common in females. Similar delay to diagnosis was observed in both groups. All the parameters for which meta-analyses were undertaken were not available from all the identified studies. Meta-analysis suggested that constitutional features (fever, and in subgroup analyses, weight loss), hypertension, headache, and sinister features of cardiomyopathy, elevated serum creatinine, and abdominal pain were more frequent in pediatric-onset TAK, corresponding with predominant vascular involvement of Hata's type IV TAK and greater frequency of splanchnic and renal artery involvement, whereas, pulse loss/pulse deficit and claudication (particularly upper limb claudication) were more frequent in adult-onset TAK, corresponding with predominant Hata's type I TAK and more frequent subclavian artery involvement. Most clinical features and vascular involvement lacked considerable heterogeneity in pooled estimates. Children with TAK also appeared to require more intense immunosuppression with more frequent use of cyclophosphamide, biologic DMARDs, tumor necrosis factor alpha inhibitors, and, in subgroup analyses, tocilizumab than in adults. Surgical or endovascular procedures, remission, and risk of dying were similar in children and adults with TAK. Considerable statistical heterogeneity was observed in the pooled drug treatments, vascular interventions, and remission.

The present systematic review included more than a thousand patients with TAK, a significantly large number

for a rare LVV [31]. The epidemiology of TAK suggests that, for reasons yet to be fully understood, TAK is more common in females [1, 32]. While previously suggested that children with TAK have greater delay to diagnosis than adults with TAK [33], the delay to diagnosis in studies identified in our systematic review was similar for both groups in a meta-analysis. Heterogenous definitions had been used for pediatric-onset TAK (≤ 18 years, < 18 years, ≤ 16 years). Future studies evaluating pediatriconset TAK should consider using the standardized definition provided by EULAR/PRES/PRINTO criteria as onset ≤ 18 years [6].

Distinct syndromes of presentation and different patterns of vascular involvement were observed between pediatric-onset and adult-onset TAK. Children had more sinister vascular involvement such as splanchnic and renal vessels, as well as more severe manifestations of cardiomyopathy and renal dysfunction. Adult-onset TAK, on the other hand, had dominant upper limb vascular occlusive manifestations. These differences were confirmed by the dominant angiographic types (Hata's) of type IV in children and type I in adults. It must be noted that meta-analysis was undertaken for clinical features and vascular involvement at presentation. Vascular involvement in TAK progresses with time in a subset of patients despite immunosuppressive therapy [16]. Angiographic subtypes might also evolve with time [33], although temporal changes in angiographic classification have not been systematically studied. Future cohort studies in both pediatric-onset and adult-onset TAK should systematically report angiographic progression to enable its comparative assessment in both subgroups.

Cardiomyopathy was more frequent in pediatric-onset TAK. Cardiac involvement in TAK could occur due to coronary artery involvement or cardiac inflammation resulting in myocarditis or cardiomyopathy [34]. Our meta-analysis suggested that coronary arterial involvement was similar in both pediatric-onset and adult-onset TAK. Cardiac involvement portends greater mortality risk in TAK [34]. Rarely, cardiac involvement in TAK might be sub-clinical, detectable only on cardiac imaging [35]. Renovascular hypertension was also more frequent in pediatriconset TAK, possibly responsible for more common renal failure among pediatric-onset TAK than adult-onset TAK. Also, uncontrolled hypertension associates with myocardial dysfunction and heart failure in TAK [36]. A recent study reported that among TAK with coronary arterial involvement, pediatric-onset TAK (n=9) had earlier onset of coronary artery involvement, higher disease activity, and greater risk of coronary artery dilatation then adult-onset TAK (n=29) [37].

TAK is corticosteroid-responsive, albeit often relapses following corticosteroid taper [38]. Most patients with pediatriconset and adult-onset TAK were treated with corticosteroids in studies identified in our systematic review, and in similar proportions between groups. Cyclophosphamide is generally reserved for more severe, aggressive vascular manifestations in TAK. Biologic DMARDs are used in refractory TAK when other DMARDs have failed. Treatment with cyclophosphamide or biologic DMARDs in more patients with pediatric-onset TAK possibly reflects an aggressive or treatment-refractory course in this sub-group of TAK. It also might reflect the need for faster corticosteroid taper in children due to complications such as growth stunting and cataract [39]. In this context, it is important to reiterate that drug therapies in TAK are mostly based on observational studies. Few clinical trials have been conducted in TAK, none exclusively focused on pediatric-onset TAK. The trial of tocilizumab in TAK included some pediatric-onset TAK (inclusion criteria \geq 12 years) [40], whereas that of abatacept included only adults [41]. Janus kinase inhibitors are being increasingly used in different inflammatory rheumatic diseases [42], including in the pediatric population [43]. Recent studies have evaluated the use of Janus kinase inhibitors in TAK as well [44-46]. None of the studies analyzed in our systematic review had reported the use of Janus kinase inhibitors in pediatric-onset TAK. This shall form an interesting agenda for future research.

Despite more severe presentation, outcomes of remission and mortality were similar in pediatric-onset and adult-onset TAK in our meta-analysis. Sub-group analyses of retrospective studies (but not the overall analyses) alone suggested a greater chance of remission in adult-onset TAK than in pediatric-onset TAK. A standardized definition of remission in TAK is lacking; this is often patient-reported. Adults might better report improvement during routine clinical visits, which might explain why retrospective reviews of medical records identified higher proportions of remission in adults. The two studies that reported angiographic outcomes at different time points (6 months, at last visit) noted similar angiographic stabilization in pediatriconset and adult-onset TAK. While similar proportions of pediatric-onset and adult-onset TAK experienced mortality, these were estimates of risk ratios without accounting for event rates. Future studies on pediatric-onset TAK should consider reporting hazard ratios of outcomes (including mortality).

There were limitations to our systematic review. Most identified studies were retrospective and, therefore, have inherent limitations imposed by such a study design. None presented patient-reported outcome measures (PROMs). A previous systematic review had also identified that few studies on childhood-onset TAK had reported PROMs [47]. A paucity of identified studies did not permit the assessment of publication bias. We have compared phenotypes and outcomes between pediatric-onset and adult-onset at an aggregated level rather than as an individual patient-data meta-analysis [48]. Risk ratios (rather than rate ratios, which account for follow-up duration and, therefore, are more robust) could be reported based on the available data. We could not contact individual authors to seek primary data of their studies due to limitations of resources available for this study. To the best of our knowledge, this is the first systematic review with meta-analysis comparing pediatric-onset and adult-onset TAK. Our findings were based on searches of multiple databases and also included gray literature searches. The findings of the present study enable a better understanding of differences in TAK based on age group of onset. When large-vessel vasculitis was recognized in the last century, TAK and its counterpart giant cell arteritis (GCA) were considered different simply based on the age of presentation. However, it is now recognized that TAK and GCA are distinct diseases with distinct genetic predisposition [49] and differing patterns of vascular involvement, based on information gathered from global, multicentric studies [50-53]. It is possible that future studies might similarly delineate distinctions between pediatric-onset and adult-onset TAK. The rarity of pediatric-onset TAK when compared with adult-onset TAK makes it difficult to envisage future clinical trials in this area, unless backed by multi-centric multi-national efforts. Multicentric cohorts with a standardized data collection and standardized outcome measures (including PROMs), possibly with concurrent adult-onset TAK cohorts, might enable better understanding of the natural history of pediatric-onset TAK.

Conclusion

Systematic differences could be identified between the clinical presentation and angiographic involvement of pediatriconset and adult-onset TAK. Outcomes (including remission, relapses, and mortality) appeared to be similar between pediatric-onset and adult-onset TAK. Future multicentric cohort studies with common case record forms for data collection should help to better understand the differences between these two subsets of TAK.

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s10067-022-06318-5.

Acknowledgements Durga Prasanna Misra acknowledges support from Indian Council of Medical Research (Grant No 5/4/1-2/2019-NCD-II) for his research on Takayasu arteritis.

Author contribution The conception and design of the study—DPM, VA, AS; acquisition of data, analysis and interpretation of data—DPM, UR, CRK, PP, VA, AS; drafting the article—DPM, UR, CRK, PP; revising it critically for important intellectual content—VA, AS; final approval of the version to be submitted—DPM, UR, CRK, PP, VA, AS; agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved—DPM, UR, CRK, PP, VA, AS.

Data availability All the analyses performed for this systematic review have been reported in the main text or in the supplementary files. Data pertaining to the systematic review shall be shared on reasonable request to the corresponding author (Durga Prasanna Misra, durgapmisra@gmail.com).

Declarations

Ethical approval This article does not contain any studies with human participants or animals performed by any of the authors.

Disclosures None.

Disclaimer The funding agency had no role in the actual conduct or reporting of this systematic review.

References

- Misra DP, Wakhlu A, Agarwal V, Danda D (2019) Recent advances in the management of Takayasu arteritis. Int J Rheum Dis 22(Suppl 1):60–68. https://doi.org/10.1111/1756-185x.13285
- Singh K, Rathore U, Rai MK et al (2022) Novel Th17 lymphocyte populations, Th17.1 and PD1+Th17, are increased in Takayasu arteritis, and both Th17 and Th17.1 sub-populations associate with active disease. J Inflamm Res 15:1521–1541. https://doi.org/ 10.2147/jir.S355881
- Arnaud L, Haroche J, Mathian A, Gorochov G, Amoura Z (2011) Pathogenesis of Takayasu's arteritis: a 2011 update. Autoimmun Rev 11:61–67. https://doi.org/10.1016/j.autrev.2011.08.001
- Pugh D, Karabayas M, Basu N et al (2022) Large-vessel vasculitis Nat Rev Dis Primers 7:93. https://doi.org/10.1038/ s41572-021-00327-5
- Jennette JC, Falk RJ, Bacon PA et al (2013) 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 65:1–11. https://doi.org/10.1002/art.37715
- Ozen S, Pistorio A, Iusan SM et al (2010) EULAR/PRINTO/PRES criteria for Henoch-Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: Final classification criteria. Ann Rheum Dis 69:798–806. https://doi.org/10.1136/ard.2009.116657
- Arend WP, Michel BA, Bloch DA et al (1990) The American College of Rheumatology 1990 criteria for the classification of

Takayasu arteritis. Arthritis Rheum 33:1129–1134. https://doi.org/10.1002/art.1780330811

- Ishikawa K (1988) Diagnostic approach and proposed criteria for the clinical diagnosis of Takayasu's arteriopathy. J Am Coll Cardiol 12:964–972. https://doi.org/10.1016/0735-1097(88)90462-7
- Sharma BK, Jain S, Suri S, Numano F (1996) Diagnostic criteria for Takayasu arteritis. Int J Cardiol 54(Suppl):S141-147. https:// doi.org/10.1016/s0167-5273(96)88783-3
- Brunner J, Feldman BM, Tyrrell PN et al (2010) Takayasu arteritis in children and adolescents. Rheumatology (Oxford) 49:1806– 1814. https://doi.org/10.1093/rheumatology/keq167
- Mathew AJ, Goel R, Kumar S, Danda D (2016) Childhood-onset Takayasu arteritis: an update. Int J Rheum Dis 19:116–126. https://doi.org/10.1111/1756-185x.12718
- Goel R, Sathish Kumar T, Danda D (2019) Childhood-onset Takayasu arteritis (c-TA): current and future drug therapy. Paediatr Drugs 21:81–93. https://doi.org/10.1007/s40272-019-00327-9
- Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (eds) (2019) Cochrane Handbook for Systematic Reviews of Interventions, 2nd edn. John Wiley & Sons, Chichester (UK)
- Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. J Clin Epidemiol 134:178–189. https://doi.org/10.1016/j. jclinepi.2021.03.001
- Stroup DF, Berlin JA, Morton SC et al (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 283:2008–2012. https://doi.org/10.1001/jama.283.15.2008
- Misra DP, Rathore U, Patro P, Agarwal V, Sharma A (2021) Diseasemodifying anti-rheumatic drugs for the management of Takayasu arteritis-a systematic review and meta-analysis. Clin Rheumatol 40:4391–4416. https://doi.org/10.1007/s10067-021-05743-2
- Misra DP, Agarwal V (2018) Systematic reviews: challenges for their justification, related comprehensive searches, and implications. J Korean Med Sci 33:9. https://doi.org/10.3346/jkms.2018.33.e92
- Wan X, Wang W, Liu J, Tong T (2014) Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol 14:135. https://doi.org/10.1186/1471-2288-14-135
- Hozo SP, Djulbegovic B, Hozo I (2005) Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 5:13. https://doi.org/10.1186/1471-2288-5-13
- Practical Meta-analysis effect size calculator. Available at https:// campbellcollaboration.org/escalc/html/EffectSizeCalculator-SMD1.php. Accessed 25 June 2022
- Cong XL, Dai SM, Feng X et al (2010) Takayasu's arteritis: clinical features and outcomes of 125 patients in China. Clin Rheumatol 29:973–981. https://doi.org/10.1007/s10067-010-1496-1
- Jales-Neto LH, Levy-Neto M, Bonfa E, de Carvalho JF, Pereira RM (2010) Juvenile-onset Takayasu arteritis: peculiar vascular involvement and more refractory disease. Scand J Rheumatol 39:506–510. https://doi.org/10.3109/03009741003742730
- Aeschlimann FA, Barra L, Alsolaimani R et al (2019) Presentation and disease course of childhood-onset versus adult-onset Takayasu arteritis. Arthritis Rheumatol 71:315–323. https://doi.org/10.1002/art.40690
- Bolek EC, Kaya Akca U, Sari A et al (2021) Is Takayasu's arteritis more severe in children? Clin Exp Rheumatol 39(Suppl 129):32– 38. https://doi.org/10.55563/clinexprheumatol/kr357t
- Karabacak M, Kaymaz-Tahra S, Şahin S et al (2021) Childhoodonset versus adult-onset Takayasu arteritis: a study of 141 patients from Turkey. Semin Arthritis Rheum 51:192–197. https://doi.org/ 10.1016/j.semarthrit.2020.10.013
- Danda D, Goel R, Joseph G et al (2021) Clinical course of 602 patients with Takayasu's arteritis: comparison between childhood-onset versus adult onset disease. Rheumatology (Oxford) 60:2246–2255. https://doi.org/10.1093/rheumatology/keaa569

- Cocchiara E, Galli E, De Fanti A, Malattia C, Ravelli A, Salvarani C (2020) SAT0489 clinical course and therapy response in Takayasu arteritis: comparision between childhood and adult onset. Ann Rheum Dis 79:1201. https://doi.org/10.1136/annrh eumdis-2020-eular.2491
- Li L, Liu C, Cheng L, Yan S, Chen H, Li Y (2021) Assessment of diagnostic utility, clinical phenotypic associations, and prognostic significance of anti-NXP2 autoantibody in patients with idiopathic inflammatory myopathies: a systematic review and metaanalysis. Clin Rheumatol 40:819–832. https://doi.org/10.1007/ s10067-020-05291-1
- Hata A, Noda M, Moriwaki R, Numano F (1996) Angiographic findings of Takayasu arteritis: new classification. Int J Cardiol 54(Suppl):S155-163
- Goel R, Gribbons KB, Carette S et al (2020) Derivation of an angiographically based classification system in Takayasu's arteritis: an observational study from India and North America. Rheumatology (Oxford) 59:1118–1127. https://doi.org/10.1093/rheum atology/kez421
- Watts RA, Hatemi G, Burns JC, Mohammad AJ (2022) Global epidemiology of vasculitis. Nat Rev Rheumatol 18:22–34. https:// doi.org/10.1038/s41584-021-00718-8
- 32. Sun Y, Yin MM, Ma LL et al (2021) Epidemiology of Takayasu arteritis in Shanghai: a hospital-based study and systematic review. Int J Rheum Dis 24:1247–1256. https://doi.org/10.1111/ 1756-185x.14183
- Misra DP, Aggarwal A, Lawrence A, Agarwal V, Misra R (2015) Pediatric-onset Takayasu's arteritis: clinical features and shortterm outcome. Rheumatol Int 35:1701–1706. https://doi.org/10. 1007/s00296-015-3272-7
- Misra DP, Shenoy SN (2017) Cardiac involvement in primary systemic vasculitis and potential drug therapies to reduce cardiovascular risk. Rheumatol Int 37:151–167. https://doi.org/10.1007/ s00296-016-3435-1
- Porter A, Youngstein T, Babar S, Mason JC (2021) A rare life-threatening presentation of Takayasu arteritis. Rheumatology (Oxford) 60:iii6-iii8. https://doi.org/10.1093/rheumatology/keab036
- 36. Guha Sarkar P, Bansal A, Tyagi S, Gupta MD (2022) Predictors of left ventricular dysfunction in patients with Takayasu's arteritis: a single centre experience. Clin Exp Rheumatol 40:714–719. https://doi.org/10.55563/clinexprheumatol/53koap
- Lei C, Huang Y, Yuan S et al (2020) Takayasu arteritis with coronary artery involvement: differences between pediatric and adult patients. Can J Cardiol 36:535–542. https://doi.org/10.1016/j.cjca. 2019.08.039
- Misra DP, Rathore U, Patro P, Agarwal V, Sharma A (2021) Corticosteroid monotherapy for the management of Takayasu arteritis-a systematic review and meta-analysis. Rheumatol Int 41:1729–1742. https://doi.org/10.1007/s00296-021-04958-5
- Deshmukh CT (2007) Minimizing side effects of systemic corticosteroids in children. Indian J Dermatol Venereol Leprol 73:218– 221. https://doi.org/10.4103/0378-6323.33633
- 40. Nakaoka Y, Isobe M, Takei S et al (2018) Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study). Ann Rheum Dis 77:348–354. https:// doi.org/10.1136/annrheumdis-2017-211878
- Langford CA, Cuthbertson D, Ytterberg SR et al (2017) A randomized, double-blind trial of abatacept (CTLA-4Ig) for the treatment of Takayasu arteritis. Arthritis Rheumatol 69:846–853. https://doi.org/10.1002/art.40037

- Choy EH (2018) Clinical significance of Janus kinase inhibitor selectivity. Rheumatology (Oxford) 58:953–962. https://doi.org/ 10.1093/rheumatology/key339
- Ruperto N, Brunner HI, Synoverska O et al (2021) Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial. Lancet 398:1984–1996. https://doi.org/10.1016/s0140-6736(21)01255-1
- 44. Rathore U, Thakare DR, Patro P, Agarwal V, Sharma A, Misra DP (2022) A systematic review of clinical and preclinical evidences for Janus kinase inhibitors in large vessel vasculitis. Clin Rheumatol 41:33–44. https://doi.org/10.1007/ s10067-021-05973-4
- 45. Kong X, Sun Y, Dai X et al (2022) Treatment efficacy and safety of tofacitinib versus methotrexate in Takayasu arteritis: a prospective observational study. Ann Rheum Dis 81:117–123. https://doi.org/10.1136/annrheumdis-2021-220832
- 46. Wang J, Dai X, Ma L et al (2022) Efficacy and safety of tofacitinib versus leflunomide with glucocorticoids treatment in Takayasu arteritis: a prospective study. Semin Arthritis Rheum 55:152018. https://doi.org/10.1016/j.semarthrit.2022.152018
- 47. Misra DP, Rathore U, Patro P, Agarwal V, Sharma A (2021) Patient-reported outcome measures in Takayasu arteritis: a systematic review and meta-analysis. Rheumatol Ther 8:1073–1093. https://doi.org/10.1007/s40744-021-00355-3
- Riley RD, Lambert PC, Abo-Zaid G (2010) Meta-analysis of individual participant data: rationale, conduct, and reporting. BMJ 340:c221. https://doi.org/10.1136/bmj.c221
- Carmona FD, Coit P, Saruhan-Direskeneli G et al (2017) Analysis of the common genetic component of large-vessel vasculitides through a meta-Immunochip strategy. Sci Rep 7:43953. https:// doi.org/10.1038/srep43953
- Gribbons KB, Ponte C, Carette S et al (2020) Patterns of arterial disease in Takayasu arteritis and giant cell arteritis. Arthritis Care Res (Hoboken) 72:1615–1624. https://doi.org/10.1002/acr.24055
- Grayson PC, Maksimowicz-McKinnon K, Clark TM et al (2012) Distribution of arterial lesions in Takayasu's arteritis and giant cell arteritis. Ann Rheum Dis 71:1329–1334. https://doi.org/10. 1136/annrheumdis-2011-200795
- 52. Stamatis P (2020) Giant cell arteritis versus Takayasu arteritis: an update. Mediterr J Rheumatol 31:174–182. https://doi.org/10. 31138/mjr.31.2.174
- 53. Kermani TA (2019) Takayasu arteritis and giant cell arteritis: are they a spectrum of the same disease? Int J Rheum Dis 22(Suppl 1):41–48. https://doi.org/10.1111/1756-185x.13288

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Authors and Affiliations

Durga Prasanna Misra¹ · Upendra Rathore¹ · Chirag Rajkumar Kopp² · Pallavi Patro³ · Vikas Agarwal¹ · Aman Sharma²

Upendra Rathore upen0007@gmail.com

Chirag Rajkumar Kopp chiragkopp@gmail.com

Pallavi Patro patropallavi17@gmail.com

Vikas Agarwal vikasagr@yahoo.com; vikasagr@sgpgi.ac.in

Aman Sharma amansharma74@yahoo.com

- ¹ Department of Clinical Immunology and Rheumatology, Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow-226014, India
- ² Clinical Immunology and Rheumatology Services, Department of Internal Medicine, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh-160012, India
- ³ School of Telemedicine, Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow-226014, India